JP2021524451A - 最適化済みｇｐ４１結合分子及びその使用 - Google Patents

最適化済みｇｐ４１結合分子及びその使用 Download PDF

Info

Publication number
JP2021524451A
JP2021524451A JP2020564553A JP2020564553A JP2021524451A JP 2021524451 A JP2021524451 A JP 2021524451A JP 2020564553 A JP2020564553 A JP 2020564553A JP 2020564553 A JP2020564553 A JP 2020564553A JP 2021524451 A JP2021524451 A JP 2021524451A
Authority
JP
Japan
Prior art keywords
binding
domain
epitope
molecule
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020564553A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021524451A5 (https=
JPWO2019222104A5 (https=
Inventor
チャーイン カオ ラム
チャーイン カオ ラム
グンド ディードリッヒ
グンド ディードリッヒ
ジェフリー リー． ノードストローム
ジェフリー リー． ノードストローム
リキン リュウ
リキン リュウ
レスリー エス． ジョンソン
レスリー エス． ジョンソン
スコット ケーニヒ
スコット ケーニヒ
バートン エフ． ヘインズ
バートン エフ． ヘインズ
グイド フェラーリ
グイド フェラーリ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Duke University
Original Assignee
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duke University filed Critical Duke University
Publication of JP2021524451A publication Critical patent/JP2021524451A/ja
Publication of JP2021524451A5 publication Critical patent/JP2021524451A5/ja
Publication of JPWO2019222104A5 publication Critical patent/JPWO2019222104A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2815—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2020564553A 2018-05-18 2019-05-13 最適化済みｇｐ４１結合分子及びその使用 Pending JP2021524451A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862673462P 2018-05-18 2018-05-18
US62/673,462 2018-05-18
PCT/US2019/032030 WO2019222104A1 (en) 2018-05-18 2019-05-13 Optimized gp41-binding molecules and uses thereof

Publications (3)

Publication Number Publication Date
JP2021524451A true JP2021524451A (ja) 2021-09-13
JP2021524451A5 JP2021524451A5 (https=) 2022-05-16
JPWO2019222104A5 JPWO2019222104A5 (https=) 2022-05-16

Family

ID=68540936

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020564553A Pending JP2021524451A (ja) 2018-05-18 2019-05-13 最適化済みｇｐ４１結合分子及びその使用

Country Status (12)

Country Link
US (1) US20210246194A1 (https=)
EP (1) EP3794027A4 (https=)
JP (1) JP2021524451A (https=)
CN (1) CN112533945A (https=)
AU (1) AU2019269383A1 (https=)
BR (1) BR112020023432A2 (https=)
CA (1) CA3100398A1 (https=)
IL (1) IL278832A (https=)
MX (1) MX2020012309A (https=)
SG (1) SG11202011355QA (https=)
WO (1) WO2019222104A1 (https=)
ZA (1) ZA202007056B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3152235B1 (en) * 2014-05-29 2021-08-25 MacroGenics, Inc. Tri-specific binding molecules and methods of use thereof
EA201790719A1 (ru) * 2014-09-26 2017-07-31 Макродженикс, Инк. Биспецифические моновалентные диатела, которые способны связывать cd19 и cd3, а также их применения
SG11202005557TA (en) * 2017-12-12 2020-07-29 Macrogenics Inc Bispecific cd 16-binding molecules and their use in the treatment of disease
CN111647078B (zh) * 2020-06-22 2022-04-26 中国医学科学院医学生物学研究所 一种抗hiv的单克隆抗体及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8691730B2 (en) * 2007-09-14 2014-04-08 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
JP6676521B2 (ja) * 2013-03-14 2020-04-08 マクロジェニクス，インコーポレーテッド 二重特異性分子、薬学的組成物及びそれらの使用
WO2015013390A1 (en) * 2013-07-25 2015-01-29 Pincus Seth Anti-hiv dual specificity antibodies and methods of hiv treatment
UA116479C2 (uk) * 2013-08-09 2018-03-26 Макродженікс, Інк. БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ
EP3152235B1 (en) * 2014-05-29 2021-08-25 MacroGenics, Inc. Tri-specific binding molecules and methods of use thereof
EP3201227A4 (en) * 2014-09-29 2018-04-18 Duke University Bispecific molecules comprising an hiv-1 envelope targeting arm
WO2016168758A1 (en) * 2015-04-17 2016-10-20 Igm Biosciences, Inc. Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof
AU2016334051B2 (en) * 2015-10-06 2023-10-26 Alector Llc Anti-TREM2 antibodies and methods of use thereof
MX2018014950A (es) * 2016-06-07 2019-04-25 Macrogenics Inc Terapia de combinacion.

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
GUIDO FERRARI ET AL., NATURE REVIES DRUG DISCOVERY, vol. 15, JPN6023014359, December 2016 (2016-12-01), pages 823 - 834, ISSN: 0005193947 *
JAMES J. STEINHARDT ET AL., NATURE COMMUNICATIONS, vol. 9, JPN6023014360, 28 February 2018 (2018-02-28), pages 877, ISSN: 0005193948 *
MARK L CHIU AND GARY L GILILAND, CURRENT OPINION IN STRUCTURAL BIOLOGY, vol. 38, JPN6023014358, June 2016 (2016-06-01), pages 163 - 173, ISSN: 0005193945 *
RUIZHONG SHEN ET AL., THE JOURNAL OF IMMUNOLOGY, vol. 184, no. 7, JPN6023014362, 1 April 2010 (2010-04-01), pages 3648 - 3655, ISSN: 0005032638 *
SAMPA SANTRA ET AL,, PLOS PATHOGENS, JPN7023001438, 3 August 2015 (2015-08-03), pages 1 - 38, ISSN: 0005193944 *
ULRICH BRINKMANN AND ROLAND E. KONTERMANN, MABS, vol. 9, no. 2, JPN7023001439, 2017, pages 182 - 212, ISSN: 0005193946 *
YAOXING HUANG ET AL., CELL, vol. 165, no. 7, JPN6023014361, 16 June 2016 (2016-06-16), pages 1621 - 1631, ISSN: 0005193949 *

Also Published As

Publication number Publication date
BR112020023432A2 (pt) 2021-02-23
MX2020012309A (es) 2021-06-08
SG11202011355QA (en) 2020-12-30
EP3794027A4 (en) 2022-02-09
IL278832A (en) 2021-01-31
US20210246194A1 (en) 2021-08-12
WO2019222104A1 (en) 2019-11-21
CN112533945A (zh) 2021-03-19
ZA202007056B (en) 2021-10-27
AU2019269383A1 (en) 2020-12-10
EP3794027A1 (en) 2021-03-24
CA3100398A1 (en) 2019-11-21

Similar Documents

Publication Publication Date Title
TWI788327B (zh) 能夠結合cd137和腫瘤抗原的雙特異性結合分子及其用途
TWI773646B (zh) 結合lag-3的分子和其使用方法
JP6647222B2 (ja) 三重特異性結合分子及びその使用方法
JP7745602B2 (ja) 変異型ｃｄ３結合ドメイン、及び疾患の治療のための併用療法におけるその使用
JP2019517539A (ja) 併用療法
JP2019506444A (ja) Ｐｄ‐１及びｃｔｌａ‐４との免疫応答性を有する二重特異性並びにその使用方法
TW201730212A (zh) Ｒｏｒ１－結合分子及其使用方法
TWI814758B (zh) 雙特異性ｃｄ１６-結合分子及其在疾病治療中的用途
KR20190099247A (ko) Adam9-결합 분자, 및 이것의 사용 방법
JP2021524451A (ja) 最適化済みｇｐ４１結合分子及びその使用
WO2021167885A1 (en) Cd137 binding molecules and uses thereof
JP7378567B2 (ja) Ｌａｇ‐３結合分子及びその使用方法
BR112017026330B1 (pt) Molécula de ligação de lag-3 que compreende um domínio de ligação a lag-3 capaz de se ligar tanto ao lag-3 humano quanto ao lag-3 de macaco cynomolgus

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220506

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220506

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230410

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20231110